Status:
COMPLETED
Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Cerebrovascular Accident
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.
Eligibility Criteria
Inclusion
- clinically defined lacunar syndrome 3 months before inclusion
- small deep infarct on diffusion MRI (Diffusion Weighted Imaging)
- no atherothrombotic, cardio-embolic, or other rarer cause.
Exclusion
- patients with past coronary event
- contra-indication for assessment of vasomotor reactivity
- patients being on statin therapy at the time of brain infarction
- contra-indication for statin therapy
- patient still under statin therapy
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT00163150
Start Date
June 1 2003
End Date
February 1 2006
Last Update
February 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Paris, France, 75877